Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response
Adult
Male
0301 basic medicine
0303 health sciences
Macrophages
Kaplan-Meier Estimate
Middle Aged
Kidney Neoplasms
3. Good health
03 medical and health sciences
Lymphocytes, Tumor-Infiltrating
Treatment Outcome
T-Lymphocyte Subsets
Immune System
Biomarkers, Tumor
Tumor Microenvironment
Humans
Female
Immunotherapy
Carcinoma, Renal Cell
Aged
DOI:
10.1111/cei.13567
Publication Date:
2020-12-21T23:58:52Z
AUTHORS (21)
ABSTRACT
A clearer understanding of the tumor immune microenvironment (TIME) in metastatic clear cell renal carcinoma (ccRCC) may help to inform precision treatment strategies. We sought identify clinically meaningful TIME signatures ccRCC. studied tumors from 39 patients with ccRCC using quantitative multiplexed immunofluorescence and relevant marker panels. Cell densities were analyzed three regions interest (ROIs): core, tumor-stroma interface stroma. Patients stratified into low- high-marker density groups median values as thresholds. Log-rank Cox regression analyses while controlling for clinical variables used compare survival outcomes patterns distributions. There significant associations increased macrophage (CD68+ CD163+ CD206+ ) poor across multiple ROIs primary tumors. In tumors, T-bet+ T helper type 1 (Th1) was highest at tumor-stromal (P = 0·0021), co-expression CD3 T-bet associated improved overall 0·015) after immunotherapy 0·014). samples, decreased forkhead box protein 3 (FoxP3)+ regulatory correlated 0·016). Increased markers Th1 within outcomes. Immune such FoxP3 showed consistent levels TIME, whereas others, T-bet, demonstrated variance distinct ROIs. These findings suggest that profiling outside core
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (31)
CITATIONS (30)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....